hepcidin production

DS28120313 is an oral inhibitor of hepcidin production (IC50: 0.093 μM).

Zilurgisertib fumarate (INB-000928 fumarate) is a potent and selective inhibitor of Activin Receptor-Like Kinase 2 (ALK2/ACVR1). It significantly inhibits ALK2 kinase activity (IC50 = 15 nM) and downregulates BMP-6-induced SMAD1/5 phosphorylation (IC50 = 63 nM). By blocking ALK2-mediated signaling, Zilurgisertib suppresses the production of hepcidin in hepatocytes (IC50 = 20 nM), thereby modulating iron metabolism. In preclinical studies, Zilurgisertib demonstrates the potential to improve anemia in cancer-induced models by effectively increasing hemoglobin levels.

Sapablursen is an antisense oligonucleotide that reduces the production of TMPRSS6, thereby increasing serum hepcidin levels. Serum hepcidin is a crucial regulator of iron homeostasis. Sapablursen can be used in studies of hematological disorders, such as polycythemia vera.

Sapablursen sodium is an antisense oligonucleotide that reduces the production of TMPRSS6, leading to increased expression of serum hepcidin, which is a key regulator of iron homeostasis. Sapablursen may be used in research on blood disorders such as polycythemia vera.

Rusfertide, a peptide mimetic of natural hepcidin, targets and degrades ferroportin, thereby reducing serum iron and transferrin saturation, which helps regulate red blood cell production. It ameliorates conditions such as polycythemia vera, β-thalassemia, and hereditary hemochromatosis [1] [2].